Credit is awarded in the calendar year the assessment is completed. AAPP reports continuing credit for ACPE (CPE Monitor) and BCPP Recertification (BPS) within days of successful exam completion.
Target Audience
This self-study activity serves as an educational tool for pharmacists seeking Board Certified Psychiatric Pharmacist (BCPP) Recertification credit and other pharmacists and health care providers seeking advanced education in patient management, disease state management, information management, and health policy and practice management in the field of psychiatric pharmacy.
Course Requirements
To satisfactorily complete the recertification programming and receive BCPP Recertification and ACPE credit, candidates must meet the following requirements:
- Register for this course.
- Complete the pre-test before starting the activity.
- Review the full content of the activity and reflect upon its teachings.
- Abide by a confidentiality and honesty statement requiring individual completion of the course.
- Complete the post-test at the end of the activity no later than the closing activity date.
- Complete an activity evaluation form.
- Wait for an official review of exam questions within 4 weeks following the closing date.
- Receive a passing grade (78%).
- Partial credit is not provided; your exam score must meet or exceed the cut-off score in order to receive the ACPE and BCP Recertification credit.
- Learners who do not achieve a passing score on a post-activity assessment may appeal assessment questions and/or take a remediation assessment. View AAPP's Post-Activity Assessment Appeal and Remediation Policy.
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Learning Objectives
| Article Number | Topic | Article and Learning Objectives |
|---|---|---|
| 1 | How to compare results of placebo-controlled trials across different medications | Article 1 on “Using Matching-Adjusted Indirect Comparisons and Network Meta-analyses to Compare Efficacy of Brexanolone Injection with Selective Serotonin Reuptake Inhibitors for Treating Postpartum Depression” is complimented by a 1 hour recorded webinar by Dr. Roger Sommi, PharmD, BCPP, assisting you as the learner in making accurate interpretations of the article. You are encouraged to read the article first and then watch the webinar while keeping the article open for frequent referral back to sections as guided by Dr. Sommi. Cooper, M.C., Kilvert, H.S., Hodgkins, P. et al. Using Matching-Adjusted Indirect Comparisons and Network Meta-analyses to Compare Efficacy of Brexanolone Injection with Selective Serotonin Reuptake Inhibitors for Treating Postpartum Depression. CNS Drugs 33, 1039–1052 (2019). https://doi.org/10.1007/s40263-019-00672-w The Recertification Editorial Board generally avoids using industry-sponsored trials for our literature analysis product. This study compares data from Phase II and III brexanolone trials to published trials of pharmacotherapy for the same indication. Most studies of this type are completed by the manufacturer because individual patient data is needed for this type of comparison. As this article is accompanied by a webinar, potential areas of bias can be addressed.
|
| 2 | Schizophrenia | Jürgens G, Andersen SE, Rasmussen HB, et al. Effect of Routine Cytochrome P450 2D6 and 2C19 Genotyping on Antipsychotic Drug Persistence in Patients With Schizophrenia: A Randomized Clinical Trial. JAMA Netw Open. 2020;3(12):e2027909. doi:10.1001/jamanetworkopen.2020.27909
|
| 3 | Suicide | Katz IR, Rogers MP, Lew R, et al. Lithium Treatment in the Prevention of Repeat Suicide-Related Outcomes in Veterans With Major Depression or Bipolar Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2022;79(1):24–32. doi:10.1001/jamapsychiatry.2021.3170
|
| 4 | Migraine Consensus Guideline | Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-1039. doi: 10.1111/head.14153. Epub 2021 Jun 23. PMID: 34160823.
|
| 5 | Transition in Care | Gryglewicz, K., Peterson, A., Nam, E., Vance, M. M., Borntrager, L., & Karver, M. S. (2021). Caring transitions—A care coordination intervention to reduce suicide risk among youth discharged from inpatient psychiatric hospitalization. Crisis: The Journal of Crisis Intervention and Suicide Prevention. Advance online publication. https://doi.org/10.1027/0227-5910/a000795
|
| 6 | Depression in Epilepsy | Mula M, Brodie MJ, deToffol B, Guekht A, Hecimovic H, Kanemoto K, et al. ILAE clinical practice recommendations for the medical treatment of depression in adults with epilepsy. Epilepsia. 2022;63:316–334. https://doi.org/10.1111/epi.17140
|
| 7 | Anxiety Disorders | Jerome, L., Feduccia, A.A., Wang, J.B. et al. Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacology 237, 2485–2497 (2020). https://doi.org/10.1007/s00213-020-05548-2
|
| 8 | Buprenorphine Initiation and Dosing | Ahmed S, Bhivandkar S, Lonergan BB, Suzuki J. Microinduction of buprenorphine/naloxone: a review of the literature. Am J Addict. 2021;30(4):305-15.
|
Continuing Education Credit and Disclosures
Activity Dates: 02/23/2023 - 11/30/2023
ACPE Contact Hours: 10
ACPE Number: 0284-0000-23-002-H01-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.
The American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Literature Analysis product is an application-based program approved for 10 hours of ACPE credit. To receive ACPE credit, pharmacists completing this programming are required to complete an evaluation of the course as well as pass an online examination. BCPP Recertification credit is earned and reported within the year the assessment is successfully completed.
Board Certified Psychiatric Pharmacists (BCPPs) may also receive 10 hours of BCPP Recertification Credit for the Literature Analysis upon successful completion of an online examination.
The American Association of Psychiatric Pharmacists is approved as a Professional Development Provider for the Board Certified Psychiatric Pharmacist (BCPP) specialty by the Board of Pharmacy Specialties (BPS). This course is part of a 10 hour BCPP recertification product earned after successful completion of the associated BCPP recertification examination for the full product.
AAPP reports continuing credit for ACPE (CPE Monitor) and BCPP Recertification (BPS) within days of successful exam completion.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
View planning committee disclosures
2023 Recertification Editorial Board
| Marissa Cullen, PharmD, BCPP Clinical Pharmacist UPMC Western Psychiatric Hospital Pittsburgh, PA No Relevant Financial Relationships to Disclose |
Beth DeJongh, PharmD, BCPS, BCPP Director of Continuing Professional Development American Association of Psychiatric Pharmacists Lincoln, NE No Relevant Financial Relationships to Disclose |
Alisha D. Donat, PharmD, BCPP Clinical Pharmacy Specialist - Mental Health South Texas Veterans Health Care System San Antonio, TX No Relevant Financial Relationships to Disclose |
| Traci M. Dutton, PharmD, BCPP, BCPS Clinical Pharmacy Specialist - Mental Health; Program Director - PGY2 Psychiatric Pharmacy Residency VA Tennessee Valley Healthcare System Murfreesboro, TN Employment: Tennessee Valley VA Healthcare System, Clinical Pharmacy Specialist - Mental Health, Member of VA PBM Educational Advisory Committee which oversees Board Certification Study Groups |
 Megan J. Ehret, PharmD, BCPP, MS |
| Abigail Hampton, PharmD, BCPP Psychiatric Clinical Pharmacist - Ambulatory University of Kansas Health System Kansas City, KS No Relevant Financial Relationships to Disclose |
Jordan Haygood, PharmD, BCPP Clinical Pharmacy Specialist - Psychiatry Medical University of South Carolina Charleston, SC No Relevant Financial Relationships to Disclose |
| Courtney A. Iuppa, PharmD, BCPP Clinical Pharmacy Manager & Residency Program Director Center for Behavioral Medicine Kansas City, MO No Relevant Financial Relationships to Disclose |
| Archana R. Jhawar, PharmD, BCPP Clinical Pharmacist Jesse Brown VAMC/ UIC College of Pharmacy Chicago, IL No Relevant Financial Relationships to Disclose |
| Dongmi Kim, PharmD, BCPP, BCPS Assistant Clinical Professor Fairleigh Dickinson University School of Pharmacy Florham Park, NJ No Relevant Financial Relationships to Disclose |
| Jamie C. Kneebusch, PharmD, BCPP, BCPS Assistant Clinical Faculty UC San Diego, Skaggs School of Pharmacy La Jolla, CA No Relevant Financial Relationships to Disclose |
| Amber R. Lemons, PharmD, BCPP Director, Educational Strategy Clinical Care Options Littleton, CO No Relevant Financial Relationships to Disclose |
| Linda D. Logan, PharmD, BCACP, BCPP, BCPS Public Service Associate University of Georgia Athens, GA Educational Grants, Research Grants or Contracts: HRSA Graduate Psychology Education Grant, CPNP Foundation Student Grant (Advisor), UGA College Pharmacy Ansel Fund |
Megan Maroney, PharmD, BCPP Clinical Associate Professor Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey Long Branch, NJ External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Pharmacy Times - speaker and medical writing honoraria, Otsuka Pharmaceuticals - Excel Speakers Bureau (former, through March 2022), Novus Medical Education - consultant/medical writing, Boehringer Ingelheim - advisory board, Sunovion Pharmaceuticals - consultant/advisory board, Biogen and Sage Therapeutics - advisory board |
| Monica Mathys, PharmD, BCGP, BCPP Professor Texas Tech University School of Pharmacy Dallas, TX Non-Financial Interests: CPNP Foundation Board member |
| Jessica L. Mulhollan, PharmD, BCPP Clinical Pharmacy Specialist, Substance Use Disorders and Mental Health Clinical Pharmacy Supervisor Louis Stokes Cleveland VA Medical Center Cleveland, OH No Relevant Financial Relationships to Disclose |
| Kristen Neumeister, PharmD, BCPP Clinical Pharmacist North Texas State Hospital Fort Worth, TX No Relevant Financial Relationships to Disclose |
| Megan O'Connell, PharmD, BCPP Advanced Practice Pharmacist - Psychiatry University of Maryland - Clifton T. Perkins Hospital jessup, MD No Relevant Financial Relationships to Disclose |
| Melissa C. Palmer, PharmD, BCPP, BCPS Clinical Pharmacy Specialist - Mental Health Alaska VA Healthcare System Anchorage, AK No Relevant Financial Relationships to Disclose |
| Brittany L. Parmentier, PharmD, BCPS, BCPP Clinical Pharmacy Specialist in Psychiatry The Harris Center for Mental Health and IDD Houston, TX No Relevant Financial Relationships to Disclose |
| Jake R. Peters, PharmD, BCPP, BCPS Assistant Professor of Pharmacy Practice/Clinical Pharmacy Specialist - Psychiatry Butler University College of Pharmacy/Indiana University Health Indianapolis, IN No Relevant Financial Relationships to Disclose |
| Sarah J. Popish, PharmD, BCPP VA PBM Academic Detailing Services, Program Manager Department of Veterans Affairs Sarasota, FL No Relevant Financial Relationships to Disclose |
 Kara R. Wong, PharmD, BCPPChair Clinical Pharmacist Practitioner, Mental Health Minneapolis VA Health Care System Minneapolis, MN No Relevant Financial Relationships to Disclose |
All relevant relationships have been mitigated.
All relevant relationships have been mitigated.
View disclaimer and disclosure of off-label use
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
View fair balance and integrity statement
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in their continuing education activities.
Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse effects, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions before dispensing or administering the drug or using the drug delivery system.
Fair balance is achieved through ongoing and thorough review of all materials produced before educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.
In accordance with the Food and Drug Administration (FDA), it is disclosed that there is the potential for discussions concerning off-label uses of a commercial product/devices during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose significant relationships (and any known relationships of their spouse/partner) with commercial companies whose products or services are discussed in this activity. Significant relationships include receiving research grants, consultant fees, travel, other benefits from a commercial company, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
AAPP planners and managers have no relationships to disclose related to the content of this CE activity.